The emotion-filled testimony truly highlighted the dire need for new treatments and the struggle that many people impacted go through on a daily basis. There were more than 10 people who spoke at the open public hearing, including three women who had participated in the TEPEZZA Phase 2 clinical trial. As part of this day-long committee meeting, there is an open public hearing where members of the community, in this case people impacted by TED and advocates, have the opportunity to address the panel. When a company submits an application for a new medicine to the FDA, it is common for a committee of experts to review the application in a public forum. Food and Drug Administration’s (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee met to review the Biologics License Application for TEPEZZA. This type of partnership and collaboration should be emulated in other disease areas. The physician and advocacy communities were highly collaborative and supportive, which helped make the trial a success. Our clinical team was highly motivated to bring a new treatment to people impacted by TED. We began the Phase 3 clinical trial in October 2017 and because this particular disease state had no FDA-approved treatment, what really stood out for me throughout the duration of the clinical trial was the collaboration within the TED community. As TED progresses, characteristics may include: eye bulging (proptosis), misalignment of the eyes (strabismus) reported in more than 50 percent of people with TED, double vision (diplopia) reported in about 50 percent of people with TED and vision loss. For background, TED is a serious, progressive, vision threatening autoimmune disease, which is most often seen in patients with Graves’ disease. In May 2017, we acquired a company called River Vision and with it, an investigational medicine called teprotumumab (now marketed as TEPEZZA) that was being studied for a rare disease called Thyroid Eye Disease (TED). Most recently, Horizon and its employees provided 526 laptops and Wi-Fi hotspots for students at its partner school, Perspectives/IIT Math & Science Academy (MSA) in Chicago, ensuring that there would be no lack of technology and access for the under-resourced school as a result of COVID-19 and the upcoming virtual school year.The story of the approval of our new breakthrough orphan medicine and the process involved in bringing it to market makes me proud of what we do at Horizon. “This is clearly a company that gives back as it continues to pioneer new medicines to treat rare and rheumatic diseases.” “BioUtah congratulates Horizon Therapeutics on this important recognition,” said Kelvyn Cullimore, president and CEO of BioUtah. The company has also seeded more than $2 million to support various organizations focused on COVID-19 relief and racial injustice, including helping patients access medical facilities. “Through it all, we’ve stayed close to our foundational principle of doing the right thing for people, with great compassion and care.”Īmong the company’s exceptional actions, Horizon implemented a generous leave policy with 100% pay continuation to employees impacted by the virus. “It is a special honor to be recognized by PEOPLE and Great Place to Work as one of the 50 Companies That Care, especially during this challenging time,” said Tim Walbert, chairman, president and chief executive officer, Horizon. companies that went above and beyond in responding to the pandemic.The list, focused on employers with 1,000 or more employees, will be featured in the Sept. Partnering with Great Place to Work, PEOPLE identified the top U.S. Horizon Therapeutics has been named to PEOPLE’s 2020 “50 Companies That Care” list. BioUtah Member Horizon Therapeutics Named to PEOPLE’s “50 Companies That Care” List
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |